Meiragtx UK II Ltd.
Clinical Trials
13
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Natural History Study for Achromatopsia
- Conditions
- Achromatopsia
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- MeiraGTx UK II Ltd
- Target Recruit Count
- 85
- Registration Number
- NCT04124185
- Locations
- 🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia
- Conditions
- Xerostomia Due to RadiotherapyHead and Neck CancerRadiation-Induced Parotid Gland Hypofunction
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- MeiraGTx UK II Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT04043104
- Locations
- 🇺🇸
Leland Stanford Junior University, Stanford, California, United States
🇺🇸University of Louisville, Louisville, Kentucky, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Gene Therapy for Achromatopsia (CNGA3)
- Conditions
- Achromatopsia
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- MeiraGTx UK II Ltd
- Target Recruit Count
- 11
- Registration Number
- NCT03758404
- Locations
- 🇺🇸
Kellogg Eye Center, Ann Arbor, Michigan, United States
🇬🇧Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- MeiraGTx UK II Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT03349242
- Locations
- 🇺🇸
Shiley Eye Institute - UCSD, La Jolla, California, United States
🇺🇸Stanford University, Spencer Center for Vision Research, Stanford, California, United States
🇺🇸Emory Eye Centre, Atlanta, Georgia, United States
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
- Conditions
- Achromatopsia
- Interventions
- Biological: Prior exposure to AAV-CNGA3 or AAV-CNGB3
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- MeiraGTx UK II Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT03278873
- Locations
- 🇺🇸
Kellogg Eye Center, Ann Arbor, Michigan, United States
🇬🇧Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
- Prev
- 1
- 2
- Next